Patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma did not benefit in terms of event-free survival when treated with the CAR T-cell therapy tisagenlecleucel vs standard-of-care chemotherapy and transplant.
Treatment with the CAR T-cell therapy tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma was favorable in both the pivotal clinical trial and the real-world setting, according to new data made available during 2021 ASH.
High rates of undetectable minimal residual disease were found in fit patients with chronic lymphocytic leukemia who were treated with venetoclax plus either obinutuzumab or ibrutinib vs chemoimmunotherapy.
Fulvestrant plus palbociclib after aromatase inhibitor plus palbociclib led to improvements in progression-free survival for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Findings from the PACIFIC-R trial indicated that the real-world progression-free survival benefit of durvalumab was higher vs the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in unresectable stage III non–small cell lung cancer.
Findings from the phase 3 CheckMate 743 trial indicated that patients with unresectable malignant pleural mesothelioma derived a continued overall survival benefit after being treated with nivolumab and ipilimumab.